43212-41-5

Basic information

• Product Name: 2,4-Dichloro-6-methoxypyrimidine
• Synonyms: 2,4-Dichloro-6-methoxypyrimidine;2,4-Dichloro-6-methoxy-1,3-diazine;2,6-Dichloro-4-methoxypyrimidine
• CAS NO: 43212-41-5
• Molecular Formula: C₅H₄Cl₂N₂O
• Molecular Weight: 179.01
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 43212-41-5.mol

Chemical Properties

• Boiling Point: 263.2±20.0 °C(Predicted)
• Appearance: /
• Density: 1.446±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.54±0.30(Predicted)
• CAS DataBase Reference: 2,4-Dichloro-6-methoxypyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloro-6-methoxypyrimidine(43212-41-5)
• EPA Substance Registry System: 2,4-Dichloro-6-methoxypyrimidine(43212-41-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 43212-41-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichloro-6-methoxypyrimidine is used as a chemical intermediate for the preparation of piperazinyl pyrimidine derivatives. These derivatives act as γ-secretase modulators, which are important in the treatment of various neurodegenerative diseases, such as Alzheimer's disease. 2,4-Dichloro-6-methoxypyrimidine's role in the synthesis of these modulators is crucial for developing effective therapies against such conditions.
Additionally, 2,4-Dichloro-6-methoxypyrimidine is used in the synthesis of α-azinylalkylamino-substituted (thiazolylamino)pyrimidines and -pyrazines. These compounds are selective JAK2 inhibitors, which have potential applications in the treatment of various inflammatory and autoimmune diseases, as well as certain types of cancer. 2,4-Dichloro-6-methoxypyrimidine's involvement in the creation of these inhibitors highlights its significance in the development of targeted therapies for a range of medical conditions.

Upstream product

• 3764-01-0 2,4,6-trichloropyrimidine 
• 29458-38-6 6-methoxypyrimidine-2,4-diol 
• 67-56-1 methanol 
• 124-41-4 sodium methylate 

Downstream Products

• 5734-64-5 2-amino-4-chloro-6-methoxypyrimidine 
• 1218996-42-9 C₁₆H₂₀ClN₃O 
• 155-90-8 4-methoxypyrimidin-2-amine 
• 6104-41-2 4-methoxypyrimidine 
• 6320-15-6 6-chloro-2,4-dimethoxypyrimidine 

Relevant articles and documents

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS

The present invention relates to novel chemical compounds derived from pyrimidines, to the method for preparing same, to the novel intermediates obtained, to the use thereof as drugs, to the pharmaceutical compositions containing same, and to the therapeutic use thereof as AKT inhibitors.

Development of an efficient, scalable route for the preparation of a novel insulin-like growth factor-1 receptor modulator

A chromatography-free and efficient synthesis of insulin-like growth factor-1 receptor (IGF-1R) modulator is reported. Herein we describe an improved synthesis for the target compound, which features facile introduction of a novel pyrrolidinyl-pyrimidyl isoxazole 8, via in situ sulfone displacement by fluorine. The overall process consists of six chemical steps and five isolations, with introduction of the expensive triheterocyclic unit 8 towards the end of the synthesis.

Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors

Thiazol-2-yl amine was identified as an isosteric replacement for pyrazol-3-yl amine during our efforts to identify potent and selective JAK2 inhibitors. The rationale, synthesis and biological evaluation of several analogs is reported, along with the in vivo evaluation of the lead compounds.

AMINO-THIAZOLYL- PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

S-6-METH0XY-2- (2- (3- (PYRIMID-2-YL) IS0XAZ0L-5-YL) PYRROLIDIN-1-YL) -4- (5-METHYL-IH-PYRAZOL-S-YLAMINO) PYRIMIDINE AND POLYMORPHIC FORMS THEREOF AS MODULATORS OF THE INSULIN-LIKE GROWTH

There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salsts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY

A compound of formula (I) wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.

4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS

A compound of formula (I): wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm-blooded animal such as man.

Amines useful in producing pharmaceutically active CNS compounds

Disclosed are Δ9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17(20) -steroids (Va and Vb) and Δ9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.

Amines useful in producing pharmaceutically active CNS compounds

Disclosed are Δ9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17(20) -steroids (Va and Vb) and Δ9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.